Diagnosing COVID-19-associated pulmonary aspergillosis

TY - JOUR

T1 - Diagnosing COVID-19-associated pulmonary aspergillosis

AU - European Confederation of Medical Mycology

AU - International Society for Human and Animal Mycology

AU - European Society for Clinical Microbiology and Infectious Diseases Fungal Infection Study Group

AU - ESCMID Study Group for Infections in Critically Ill Patients

AU - Verweij, Paul E.

AU - Gangneux, Jean Pierre

AU - Bassetti, Matteo

AU - Brüggemann, Roger J.M.

AU - Cornely, Oliver A.

AU - Koehler, Philipp

AU - Lass-Flörl, Cornelia

AU - van de Veerdonk, Frank L.

AU - Chakrabarti, Arunaloke

AU - Hoenigl, Martin

N1 - Funding Information: PEV reports grants from Gilead Sciences, Merck, Sharp and Dohme (MSD), Pfizer, ThermoFisher, and F2G; and non-financial support from OLM Diagnostics and IMMY, outside the submitted work. J-PG reports grants and personal fees from Pfizer and MSD outside the submitted work. MB reports grants and personal fees from Pfizer, MSD, Gilead, Angelini, Basilea, Astellas, Cidara, and Shionogi; personal fees from Biomerieux, Vifor, Paratek, Nabriva, Achaogen, Menarini, Bayer, Tetraphase, Venatorx, and Vifor; and grants from Melinta, outside the submitted work. RJMB served as consultant for Astellas Pharma, F2G, Amplyx, Gilead Sciences, MSD, and Pfizer; and has received unrestricted and research grants from Astellas Pharma, Gilead Sciences, MSD, and Pfizer; all contracts were through Radboudumc, and all payments were invoiced by Radboudumc. OAC is supported by the German Federal Ministry of Research and Education; is funded by the Deutsche Forschungsgemeinschaft (German Research Foundation) under Germany's Excellence Strategy (CECAD, EXC 2030 - 390661388); has received research grants from Actelion, Amplyx, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen Pharmaceuticals, Medicines Company, MedPace, Melinta Therapeutics, MSD, Pfizer, and Scynexis; is a consultant to Actelion, Allecra Therapeutics, Amplyx, Astellas, Basilea, Biosys UK, Cidara, Da Volterra, Entasis, F2G, Gilead, Matinas, MedPace, Menarini Ricerche, Roche Diagnostics, MSD, Nabriva Therapeutics, Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Scynexis, Seres Therapeutics, Tetraphase, and Vical; and received lecture honoraria from Astellas, Basilea, Gilead, Grupo Biotoscana, MSD, and Pfizer. PK has received non-financial scientific grants from Miltenyi Biotec, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany; and is an advisor to, or received lecture honoraria from Akademie für Infektionsmedizin, Astellas Pharma, Gilead Sciences, GPR Academy Ruesselsheim, MSD, Noxxon Pharma, and University Hospital, Ludwig-Maximilians-Universität Munich, outside the submitted work. CL-F reports grants, personal fees, and payment of accomodation or travel from Gilead Sciences; grants and payment of accomodation or travel from Astellas Pharma; personal fees from MSD; personal fees and payment of accomodation or travel from Basilea; and payment of accomodation or travel from Angelini Pharma, outside the submitted work. FLvdV has served as an invited speaker for Gilead Sciences. AC declares no competing interests. MH reports grants from Pfizer and Gilead outside the submitted work.

PY - 2020/6

Y1 - 2020/6

UR - http://www.scopus.com/inward/record.url?scp=85103979264&partnerID=8YFLogxK

U2 - 10.1016/S2666-5247(20)30027-6

DO - 10.1016/S2666-5247(20)30027-6

M3 - Comment/debate

AN - SCOPUS:85103979264

SN - 2666-5247

VL - 1

SP - e53-e55

JO - The Lancet Microbe

JF - The Lancet Microbe

IS - 2

ER -